31 August 2023: Clinical Research
Associations Between Mean Platelet Volume and Various Factors in Type 2 Diabetes Patients: A Single-Center Study from Poland
Karolina Marta Gacuta 1ABCDEFG* , Olga Martyna Koper-Lenkiewicz 2ABCDEFG* , Anna Justyna Milewska 3CD , Magdalena Ćwiklińska-Dworakowska 4D , Joanna Matowicka-Karna 2D , Joanna Kamińska 2ABDEFGDOI: 10.12659/MSM.941109
Med Sci Monit 2023; 29:e941109
Table 1 Demographic, clinical, and routine laboratory data, coexisting diseases, and medications of patients with type 2 diabetes.
| Type 2 diabetes patients | |
|---|---|
| Number | 106 |
| Sex: female/male | 56/50 |
| Age, years | 70 (62–77) |
| BP systolic, mmHg | 142 (130–150) |
| BP diastolic, mmHg | 83 (80–90) |
| BMI, kg/m | 32 (27–37) |
| WBC, 10/μL | 7.66 (5.80–9.30) |
| RBC, 10/μL | 4.24 (3.88–4.62) |
| HGB, g/dL | 12.70 (11.10–13.60) |
| HCT, % | 38.25 (34.30–41.10) |
| MCV, fL | 88.60 (85.20–92.10) |
| MCH, pg | 29.10 (27.70–30.40) |
| MCHC, g/dL | 33.00 (32.10–33.70) |
| CHCM, g/dL | 32.45 (31.90–33.30) |
| RDW, fL | 14.00 (13.40–15.20) |
| HDW, g/dL | 2.67 (2.53–2.85) |
| TC, mg/dL | 160 (140–195) |
| HDL-C, mg/dL | 46 (34–56) |
| LDL-C, mg/dL | 83 (71–109) |
| TG, mg/dL | 135 (98–180) |
| INR | 1.09 (0.99–1.34) |
| PT, sec. | 13.00 (11.80–15.90) |
| Fibrinogen, mg/dL | 598 (449–779) |
| D-dimer, μg/mL | 253 (156–540) |
| Creatine, mg/dL | 1.00 (0.80–1.36) |
| eGFR, ml/min/1.73 m | 72 (49–96) |
| Hypertension | 90 (85%) |
| Hyperlipidemia | 22 (21%) |
| Obesity | 68 (64%) |
| Chronic renal failure | 34 (32%) |
| Coronary artery disease | 63 (59%) |
| Mitral valve regurgitation | 12 (11%) |
| Cardiac arrhythmias | 34 (32%) |
| Polyneuropathy | 13 (12%) |
| Stroke | 10 (9%) |
| Diabetic foot | 16 (15%) |
| Atherosclerosis of the lower limbs | 30 (28%) |
| Secondary anemia | 9 (8%) |
| Acetylsalicylic acid | 64 (60%) |
| Fibrates | 21 (20%) |
| Statins | 42 (40%) |
| Beta-blockers | 74 (70%) |
| ACE inhibitors | 85 (80%) |
| ARBs | 11 (10%) |
| Calcium channel blockers | 40 (38%) |
| Diuretics | 77 (73%) |
| Proton pump inhibitors | 15 (14%) |
| Insulin | 99 (93%) |
| Oral antidiabetic drugs | 51 (48%) |
| to convert WBC to ×10/L, multiply by 1.0; RBC to ×10/L multiply by 1.0; HGB to g/L multiply by 10.0; HCT to proportion of 1.0 multiply by 0.01; MCHC to g/L multiply by 10.0; CHCM to g/L multiply by 10.0; TC to mmol/L multiply by 0.0259; HDL-C to mmol/L multiply by 0.0259; LDL-C to mmol/L multiply by 0.0259; TG to mmol/L multiply by 0.0113; fibrinogen to μmol/L multiply by 0.0294; D-dimer to nmol/L multiply by 5.476; creatinine to μmol/L multiply by 88.4; eGFR to ml/sec multiply by 0.0167 | |
| ACE – angiotensin-converting enzyme; ARBs – angiotensin receptor blockers; BMI – body mass index; BP – blood pressure; CHCM – mean hemoglobin concentration in the red blood cell; eGFR – estimated glomerular filtration rate; HCT – hematocrit; HDL-C – high-density lipoprotein; HDW – standard deviation of hemoglobin concentration in red blood cells; HGB – hemoglobin concentration; INR – prothrombin time in the form of the International Normalized Ratio; LDL-C – low-density lipoprotein; MCH – mean mass of hemoglobin in a red blood cell; MCHC – mean concentration of hemoglobin in a red blood cell; MCV – mean red blood cell volume index; PT – prothrombin time; RBC – red blood cell count; RDW – red blood cell volume distribution range; TC – total cholesterol; TG – triglyceride; WBC – white blood cell count. Results are presented as the median and interquartile range (25 and 75 percentiles) or as numbers and percentages. | |